Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 15
Submit an article Journal homepage
114
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2

Rossana Berardi Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
,
Elena Maccaroni Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
,
Azzurra Onofri Università Politecnica delle Marche, Postgraduate School of Oncology, Ancona, Italy
,
Riccardo Giampieri Università Politecnica delle Marche, Postgraduate School of Oncology, Ancona, Italy
,
Mirco Pistelli Università Politecnica delle Marche, Postgraduate School of Oncology, Ancona, Italy
,
Alessandro Bittoni Università Politecnica delle Marche, Postgraduate School of Oncology, Ancona, Italy
,
Mario Scartozzi Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
,
Chiara Pierantoni Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
,
Alessandra Mandolesi Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Anatomia Patologica, Ancona, Italy
,
Italo Bearzi Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi di Ancona, Anatomia Patologica, Ancona, Italy
&
Stefano Cascinu Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi – G Salesi di Ancona, Medical Oncology Unit, Via Conca 71, 60020 Ancona, Italy +39 071 5965715; +39 071 5965053; [email protected]
 show all
Pages 2467-2478 | Published online: 17 Sep 2009

Bibliography

  • Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
  • Glimelius B, Oliveira J. ESMO Guidelines Working Group, Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii31-2
  • Kapitejn E, Liefers GJ, Los LC, et al. Mechanism of oncogenesis in colon versus rectal cancer. J Pathol 2001;195:171-8
  • Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-9
  • Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after pre-operative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96
  • Mohiuddin M, Hayne M, Regine WF, et al. Prognostic significance of post chemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Rad Oncol Biol Phys 2000;48:1075-80
  • Sobin LH, Wittekind CH, editors, TNM classification of malignant tumours. Sixth Edition, Wiley-Liss, New York; 2002
  • Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group [review]. Cancer 2000;88(7):1739-57
  • Royal College of Pathologists (2007) Standards and Dataset for Reporting Cancers: Dataset for colorectal cancer (2nd edition). Available from: http://www.rcpath. org/resources/pdf/G049-ColorectalDataset-Sep07.pdf
  • Baxter NN, Virnig DJ, Rothenberger DA, et al. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005;97:219-25
  • Sarli L, Bader G, Iusco D, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005;41:272-9
  • Wichmann MW, Muller C, Meyer G, et al. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 2002;137:206-10
  • Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 2007;245:543-52
  • Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-18
  • Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in oesophageal cancer regardless of neoadjuvant chemoradiation or lympadenectomy extent. Ann Surg 2008;247:365-71
  • Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706-12
  • Stocchi L, Nelson H, Sargent DJ, et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001;19:3895-902
  • Kim YS, Kim JH, Yoon SM, et al. lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;74(3):796-802
  • Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23(34):8688-96
  • Bouzourene H, Bosman FT, Seelentag W, et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94(4):1121-30
  • Goldstein NS, Armin M. Epidermal growth factor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-46
  • Yang D, Schneider S, Azuma M, et al. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer 2006;6(4):305-11
  • Giralt J, de las Heras M, Cerezo L, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005;74(2):101-8
  • Takahari D, Yamada Y, Okita NT, et al. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 2009;76(1):42-8
  • Cunningham MP, Essapen S, Thomas H, et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 2006;28(2):329-35
  • Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10
  • Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
  • Li C, Gardy R, Seon BK, et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003;88(9):1424-31
  • Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76
  • Zlobec I, Vuong T, Compton CC, et al. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008;98(2):450-6
  • Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008;98:143-7
  • Giralt J, Navalpotro B, Hermosilla E, et al. Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 2006;71(5-6):312-9
  • Nozue M, Isaka N, Fukao K. Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer. Oncol Rep 2001;8:1247-9
  • Qiu H, Sirivongs P, Rothenberger M, et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000;43:451-9
  • Noda E, Maeda K, Inoue T, et al. Predictive value of vascular endothelial growth factor-C expression for local recurrence of rectal carcinoma. Oncol Rep 2007;17(6):1327-31
  • McCormick F. Signal transduction. How receptor turns ras on. Nature 1993;63:15-16
  • Benhattar J, Losi L, Chaubert P, et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993;104:1044-8
  • Finkelstein SD, Sayegh R, Bakker A, et al. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-2
  • Senagore AJ, Thebo-Bienner J. A newly identified pattern of k-ras mutations at codons 12 and 13 is associated with long-term survival in colorectal cancer. Surgery 1997;122:765-70
  • Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 2001;85(5):692-6
  • Bouzourene H, Gervaz P, Cerottini JP, et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000;36:1008-15
  • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
  • Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience (abstract 2). J Clin Oncol 2008;26(Suppl):5s
  • Kressner U, Inganäs M, Bydin S, et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999;17:593-9
  • Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88(20):1442-55
  • Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92(3):434-44
  • Russo A, Bazan V, Iacopetta B, et al.; TP53-CRC Collaborative Study Group. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23(30):7518-28
  • Jurach MT, Meurer L, Moreira LF. Expression of the p53 protein and clinical and pathologic correlation in adenocarcinoma of the rectum. Arq Gastroenterol 2006;43(1):14-9
  • Terzi C, Canda AE, Sagol O, et al. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis 2008;23(1):37-45
  • Rau B, Sturm I, Lage H, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21(18):3391-401
  • Fernebro E, Bendahl PO, Dictor M, et al. Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer 2004;111(6):921-8
  • Kim NK, Park JK, Lee KY, et al. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 2001;8(5):418-24
  • Jakob C, Liersch T, Meyer W, et al. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. Am J Surg Pathol 2006;30:1169-74
  • Johnston PG, Drake JC, Trepel J, et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52:4306-12
  • Cascinu S, Aschele C, Barni S, et al. Thymidylate Synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999;5:1996-9
  • Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-36
  • Liersch T, Langer C, Ghadimi BM, et al. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 2006;24(25):4062-8
  • Bertolini F, Bengala C, Losi L, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;68(5):1455-61
  • Calistri D, Presciuttini S, Buonsanti G, et al. Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. Int J Cancer 2000;89:87-91
  • Hemminki A, Mecklin JP, Jarvinen H, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921-8
  • Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis [review]. J Clin Oncol 2005;23(3):609-18
  • Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007;13(13):3831-9
  • Meng WJ, Sun XF, Tian C, et al. Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients. Oncology 2007;72(1-2):82-8
  • Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126(2):394-401
  • Storojeva I, Boulay JL, Heinimann K, et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep 2005;14(1):241-9
  • Que FG, Gores GJ. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996;110:1238-43
  • Bhatavdekar JM, Patel DD, Ghosh N, et al. Coexpression of bcl-2, c-myc and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 1997;40:785-90
  • Schwandner O, Schieck THK, Bruch HP, et al. p53 and bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 2000;36:348-56
  • Sarela AI, Scott N, Ramsdale J, et al. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001;8:305-10
  • Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4
  • Rödel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65(11):4881-7
  • Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NFkappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 2000;275:36062-6
  • Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-90
  • Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-κB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007;25(25):3930-5
  • Cascinu S, Berardi R, Salvagni S, et al. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 2008;98(1):71-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.